![]() August 6, 2003 HOUSE AND SENATE
MEDICARE PRESCRIPTION DRUG BILLS INCLUDE PROPOSALS THAT WOULD AFFECT HEALTH PLANS
The House and Senate versions of the Medicare Prescription Drug and Modernization
Act of 2003 (H.R.1 and S.1) that are currently being reconciled in a Conference
Committee include provisions that would improve access to more affordable prescription
drugs for health plan participants of all ages, not only Medicare-eligible retirees.
In addition, the House bill would create new personal savings accounts that employees
could use to pay medical expenses. Improve Access to More Affordable Prescription Drugs Create New Personal Savings Accounts to Pay Medical Expenses Only the House bill contains a proposal to create two new types of tax-preferred personal
savings accounts to pay medical expenses:
Distributions for non-health expenses would be subject to income tax and a 15 percent penalty.
The Flexible Spending Arrangement "use-it-or-lose-it" rule would be modified by permitting
up to $500 of unused balances to be carried forward or transferred to an HSA or HSSA. If an
individual is not eligible for an HSA or HSSA, funds may be transferred to a tax-qualified
plan, a §403(b) plan, a §457(b) plan or an individual retirement account (IRA). The bill also addresses the issue of whether vendors of debit cards used by employees with
a flexible spending arrangement must issue a Form 1099 to providers, pharmacies and other
entities paid through the debit arrangement. The bill would clarify that no Form 1099 is
necessary. Implications for Health Plan Sponsors Because both the fact and the shape of a final bill are still uncertain, it is premature
to consider detailed changes in the design of retiree health plans and other health plans
in anticipation of whatever legislation will emerge from the Conference Committee. When
and if a Medicare prescription drug program is enacted, plan sponsors will want to review
the details carefully to determine how it will affect their health benefit programs. Outlook The outlook for enactment of prescription drug legislation is less certain than it originally
appeared. One of the most controversial issues making enactment questionable is whether the
House's proposals for HSAs and HSSAs should be included in the Medicare legislation. Cost is
a major consideration. The Congressional Budget Office estimates that the two accounts will
cost $174 billion over 10 years, with most of the cost coming from HSSAs. If Congress passes the bill that eventually emerges from the Conference Committee, President
Bush has announced his intention to sign it into law. The Segal Company will report on significant
developments regarding this legislation. |
||||||



